Add to ORKGThe Author(s) 2015. This article is published with open access at Springerlink.com Introduction: The use of dipeptidyl peptidase-4 inhibitors in combination with metformin is increasing in Japanese patients with type 2 diabetes mellitus (T2DM), but no single-pill combination (SPC) is currently available i
INTRODUCTION: Metformin is considered as the first-line drug therapy for the management of type 2 di...
Abstract: Vildagliptin is a selective and potent dipeptidyl peptidase-4 inhibitor that improves glyc...
peer reviewedIMPORTANCE OF THE FIELD: Type 2 diabetes is an increasingly prevalent disease resulting...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is pathophysiologically characterized by a combination...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: Met...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction: Sax...
Introduction: During recent years there has been a discussion of introducing initial combination the...
Serge Halimi1, Anja Schweizer2, Biljana Minic2, James Foley3, Sylvie Dejager41University Hospital of...
Background and aim: Limitations of the currently recommended stepwise treatment pathway for type 2 d...
Bo AhrénDepartment of Clinical Sciences, Division of Medicine, Lund University, Lund, SwedenA...
The single-tablet combination of vildagliptin and metformin addresses key defects of type 2 diabetes...
The single-tablet combination of vildagliptin and metformin addresses key defects of type 2 diabetes...
CY Pan,1 XL Wang21Chinese PLA General Hospital, Beijing, People's Republic of China; 2Medical Af...
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is typically progressive, with sequential addition of ...
INTRODUCTION: Metformin is considered as the first-line drug therapy for the management of type 2 di...
Abstract: Vildagliptin is a selective and potent dipeptidyl peptidase-4 inhibitor that improves glyc...
peer reviewedIMPORTANCE OF THE FIELD: Type 2 diabetes is an increasingly prevalent disease resulting...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is pathophysiologically characterized by a combination...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: Met...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction: Sax...
Introduction: During recent years there has been a discussion of introducing initial combination the...
Serge Halimi1, Anja Schweizer2, Biljana Minic2, James Foley3, Sylvie Dejager41University Hospital of...
Background and aim: Limitations of the currently recommended stepwise treatment pathway for type 2 d...
Bo AhrénDepartment of Clinical Sciences, Division of Medicine, Lund University, Lund, SwedenA...
The single-tablet combination of vildagliptin and metformin addresses key defects of type 2 diabetes...
The single-tablet combination of vildagliptin and metformin addresses key defects of type 2 diabetes...
CY Pan,1 XL Wang21Chinese PLA General Hospital, Beijing, People's Republic of China; 2Medical Af...
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is typically progressive, with sequential addition of ...
INTRODUCTION: Metformin is considered as the first-line drug therapy for the management of type 2 di...
Abstract: Vildagliptin is a selective and potent dipeptidyl peptidase-4 inhibitor that improves glyc...
peer reviewedIMPORTANCE OF THE FIELD: Type 2 diabetes is an increasingly prevalent disease resulting...